Join
Live feed
·
PRReleasevia Quantisnow
Boundless Bio Inc. logo

Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
BOLD· Boundless Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BOLD (Boundless Bio Inc.) and more on Quantisnow.